Accepted for Publication: September 2, 2022.
Published Online: November 7, 2022. doi:10.1001/jamaneurol.2022.3881
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 LaRovere KL et al. JAMA Neurology.
Corresponding Author: Adrienne G. Randolph, MD, Boston Children’s Hospital, 300 Longwood Ave, Bader 634, Boston, MA 02115 (email@example.com).
Author Contributions: Dr Randolph had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: LaRovere, Poussaint, Young, Walker, Fitzgerald, Hobbs, Schwarz, Zambrano, Randolph.
Acquisition, analysis, or interpretation of data: LaRovere, Poussaint, Young, Newhams, Kucukak, Irby, Kong, Schwartz, Bembea, Wellnitz, Havlin, Cvijanovich, Hall, Fitzgerald, Schuster, Hobbs, Halasa, Singh, Mack, Bradford, Gertz, Typpo, Loftis, Giuliano, Horwitz, Biagas, Clouser, Rowan, Maddux, Soma, Babbitt, Aguiar, Kolmar, Heidemann, Harvey, Campbell, Randolph.
Drafting of the manuscript: LaRovere, Poussaint, Hobbs.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Young.
Obtained funding: Zambrano, Randolph.
Administrative, technical, or material support: Poussaint, Newhams, Kucukak, Kong, Hall, Fitzgerald, Hobbs, Singh, Mack, Bradford, Typpo, Loftis, Babbitt, Kolmar, Zambrano, Campbell, Randolph.
Supervision: LaRovere, Schuster, Hobbs, Singh, Schwarz, Campbell, Randolph.
Conflict of Interest Disclosures: Dr Poussaint reported grants from the National Institutes of Health (NIH) for the PBTC Neuroimaging Center and personal fees from Springer Publishing outside the submitted work. Dr Bembea reported grants from the NIH, National Institute of Neurological Disorders and Stroke, and Grifols outside the submitted work. Dr Hall reported personal fees for serving on data and safety monitoring boards from AbbVie and La Jolla Pharmaceutical, personal fees from the American Board of Pediatrics Service for subboard service outside the submitted work, and patents for WO 2020/168250 and WO 2020/168254, both licensed to Kiadis. Dr Schuster reported grants from Merck outside the submitted work. Dr Hobbs reported consulting fees from Biomerieux and dynamed.com outside the submitted work. Dr Halasa reported grants from Sanofi and Quidel outside the submitted work. Dr Rowan reported grants from the National Heart, Lung, and Blood Institute outside the submitted work. Dr Randolph reported royalties from UpToDate and grants from the NIH outside the submitted work. No other disclosures were reported.
Funding/Support: This investigation was funded by the Centers for Disease Control and Prevention under a contract to Boston Children’s Hospital.
Role of the Funder/Sponsor: The funder participated in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript; had a role in the decision to submit the manuscript for publication and the choice of journal; and had the right to veto publication.
Group Information: Additional members of the Overcoming COVID-19 Investigators are listed in Supplement 2.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Additional Contributions: We appreciate and thank the many research coordinators at the Overcoming COVID-19 hospitals who assisted in data collection for this investigation. We thank the leadership of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network for their ongoing support.
KL , Riggs
BJ , Poussaint
et al; Overcoming COVID-19 Investigators. Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome. JAMA Neurol
. 2021;78(5):536-547. doi:10.1001/jamaneurol.2021.0504PubMedGoogle ScholarCrossref
V , Gerdes
ME , Shi
et al. Characteristics and clinical outcomes of children and adolescents aged <18 years hospitalized with COVID-19: six hospitals, United States, July-August 2021. MMWR Morb Mortal Wkly Rep
. 2021;70(5152):1766-1772. doi:10.15585/mmwr.mm705152a3PubMedGoogle ScholarCrossref
M , Woodworth
KR , Gargano
et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years: United States, May 2021. MMWR Morb Mortal Wkly Rep
. 2021;70(20):749-752. doi:10.15585/mmwr.mm7020e1PubMedGoogle ScholarCrossref
KR , Moulia
D , Collins
et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years: United States, November 2021. MMWR Morb Mortal Wkly Rep
. 2021;70(45):1579-1583. doi:10.15585/mmwr.mm7045e1PubMedGoogle ScholarCrossref
A , Tunkel
AR , Bloch
et al; International Encephalitis Consortium. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the International Encephalitis Consortium. Clin Infect Dis
. 2013;57(8):1114-1128. doi:10.1093/cid/cit458PubMedGoogle ScholarCrossref
BE , Hallisey
EJ , Adams
E , Lavery
A . Measuring community vulnerability to natural and anthropogenic hazards: the Centers for Disease Control and Prevention’s Social Vulnerability Index. J Environ Health
. 2018;80(10):34-36.PubMedGoogle Scholar
KA , Nyberg
T , Zaidi
et al; COVID-19 Genomics UK (COG-UK) consortium. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis
. 2022;22(1):35-42. doi:10.1016/S1473-3099(21)00475-8PubMedGoogle ScholarCrossref
LB , Tardieu
M , Amato
et al; International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler
. 2013;19(10):1261-1267. doi:10.1177/1352458513484547PubMedGoogle ScholarCrossref
STJ , Abdel-Mannan
O , Sa
et al; CoroNerve study group. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc Health
. 2021;5(9):631-641. doi:10.1016/S2352-4642(21)00193-0PubMedGoogle ScholarCrossref
LD , Newhams
MM , Olson
et al; Overcoming COVID-19 Investigators. BNT162b2 mRNA vaccination against COVID-19 is associated with decreased likelihood of multisystem inflammatory syndrome in U.S. children ages 5-18 years. Clin Infect Dis
. 2022;ciac637. doi:10.1093/cid/ciac637PubMedGoogle ScholarCrossref